cagrilintide phase 3 Novo Nordisk's CagriSema outperforms Ozempic in III trial Amylin Injectable Cagrilintide Demonstrates Weight

Medical and Editorial Review This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below

Patients who are not candidates for GLP-1s or want additional support alongside lifestyle changes

Only increase if weight loss stalls for 3 or more consecutive weeks, appetite suppression fades before your next injection, or your prescriber recommends escalation based on your individual progress

Open questions also include an unresolved debate in the peer-reviewed literature about the implications of BPC-157s pro-angiogenic activity for cancer-relevant signaling pathways, raised in a 2025 literature review and disputed by the original research group